Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 61 results for diabetic foot

  1. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

    Medtech innovation briefing
    Published
    1 June 2021

  2. When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?...

    Research recommendation
    Published
    15 November 2019

  3. When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?...

    Research recommendation
    Published
    15 November 2019

  4. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

    Medtech innovation briefing
    Published
    19 November 2014

  5. What is the effectiveness of different footwear, insoles and orthoses in the prevention of foot problems?

    prevention of foot problems? Any explanatory notes(if applicable) Source guidance details Comes from guidance Diabetic foot...

    Research recommendation
    Published
    15 November 2019

  6. Within the hospital multidisciplinary team, when is it appropriate and effective to refer people with diabetes who have foot problems to specialist services such as investigative or interventional radiology, orthopaedic or vascular services, specialist pain management and specialist orthotics?

    when is it appropriate and effective to refer people with diabetes who have foot problems to specialist services such as investigative...

    Research recommendation
    Published
    15 November 2019

  7. What strategies may be useful in the prevention of Charcot arthropathy?

    applicable) Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date

    Research recommendation
    Published
    15 November 2019

  8. When is it safe to stop contact casting in the treatment of acute Charcot arthropathy?

    applicable) Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date

    Research recommendation
    Published
    18 November 2019

  9. Which risk stratification tools can be used to predict the likelihood of Charcot arthropathy?

    applicable) Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date

    Research recommendation
    Published
    18 November 2019

  10. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

    Evidence summary
    Published
    5 January 2021

  11. Prevention strategies for Charcot arthropathy:- What strategies may be useful in the prevention of Charcot arthropathy?

    sequelae. Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date

    Research recommendation
    Published
    12 October 2015

  12. Type 2 diabetes prevention: population and community-level interventions (PH35)

    This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.

    Public health guideline
    Published
    10 May 2011
    View recommendations

    Sections for PH35

  13. Additional research could help address uncertainties in the evidence, although the case for cost savings remains unlikely. Although the committee acknowledged that the Game et al. (2018) RCT was well conducted, it felt that additional research could help resolve some uncertainties around the cost and clinical case for 3C Patch. Specifically, research identifying the most appropriate stopping rule, and the associated clinical outcomes of implementing the rule, would help address key uncertainties within the cost case. Additional collection of resource use data on unhealed hard-to-heal ulcers could also reduce uncertainty in the cost case. Further to this, evidence could be collected on an UrgoStart-experienced population, as this would be reflective of current NHS care. Clinical experts thought a trial on this population would be feasible. The committee concluded that although further research could be done, on balance it was unlikely to result in a cost-saving case for 3C Patch based on the decision problem evaluated in this guidance

    guidance details Comes from guidance 3C Patch for treating diabetic foot ulcers Number MTG66 Date issued March 2022

    Research recommendation
    Published
    8 April 2022

  14. Diabetes: annual foot examination (children T2DM) (IND309)

    This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    16 April 2025

  15. Diabetes: annual foot examination (children T1DM) (IND308)

    This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    16 April 2025